Sequence-dependent internalisation of aggregating peptides by Couceiro, Jose R et al.
Size	  dependent	  uptake	  of	  peptide	  aggregates	  
1 
	  
This research was originally published in The Journal of Biological Chemistry. 
Jose R. Couceiro,  Rodrigo Gallardo,  Frederik De Smet,  Greet De Baets, Pieter 
Baatsen,  Wim Annaert,  Kenny Roose,  Xavier Saelens,  Joost Schymkowitz, 
and Frederic Rousseau 
Sequence-dependent internalisation of aggregating peptides.  
J. Biol. Chem First Published on November 12, 
2014,doi:10.1074/jbc.M114.586636. © the American Society for Biochemistry and 
Molecular Biology 
 
Sequence-dependent internalisation of aggregating peptides 
José R. Couceiro1,2, Rodrigo Gallardo1,2, Frederik De Smet1,2, Greet De Baets1,2, Pieter Baatsen3,4, 
Wim Annaert5, Kenny Roose6,7, Xavier Saelens6,7, Joost Schymkowitz1,2 and Frederic Rousseau1,2 
1 Switch Laboratory, VIB, Leuven, Belgium 
2 Switch Laboratory, Department of Cellular and Molecular Medicine, KULeuven, Belgium 
3Electron microscopy facility (EMoNe), KU Leuven Centre for Human Genetics, Belgium 
4 VIB BIO Imaging Core, VIB, Leuven, Belgium 
5Laboratory for Membrane Trafficking, KU Leuven and VIB-Centre for the Biology of Disease, Leuven, 
Belgium 
6VIB Inflammation Research Center, 9052 Ghent, Belgium 
7Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium 
 
*Running title: Size dependent uptake of peptide aggregates 
To whom correspondence should be addressed: Frederic Rousseau, Switch Laboratory, Department of 
Cellular and Molecular Medicine, Gasthuisberg Campus O&N1, Herestraat 49 bus 802, B-3000 Leuven, 
Belgium. Tel.: (+32) 16 3 72572; Fax: (+32) 16 3 72571; E-mail: frederic.rousseau@switch.vib-
kuleuven.be 
 
Keywords: Protein aggregation; Prionoid; Cellular Uptake; Chaperones; Endocytosis 
Background: Prionoid propagation requires cells 
internalization of aggregated polypeptides. 
Results: Aggregates of different sequence are 
internalized through different endocytic pathways. 
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Only phagocytozed aggregates (>1 µm) elicit an 
HSF1-dependent proteostatic response. 
Conclusion: Proteostatic response upon aggregate 
internalization differs markedly  depending on the 
sequence. 
Significance: The characterisation of mechanisms 
of cell penetration is fundamental for the 
understanding of aggregate transmission in 
disease. 
ABSTRACT 
Recently a number of aggregation disease 
polypeptides have been shown to spread from 
cell to cell thereby displaying prionoid 
behaviour. Studying aggregate internalisation 
however is often hampered by the complex 
kinetics of the aggregation process resulting in 
the concomitant uptake of aggregates of 
different sizes by competing mechanisms, which 
makes it difficult to isolate pathway-specific 
responses to aggregates. We designed synthetic 
aggregating peptides bearing different 
aggregation propensities with the aim of 
producing modes of uptake that are sufficiently 
distinct to differentially analyse the cellular 
response to internalization. We found that 
small acidic aggregates (≤500 nm diameter) 
were taken up by non-specific endocytosis as 
part of the fluid phase and travelled through 
the endosomal compartment to lysosomes. By 
contrast, basic aggregates bigger (>1 µm) were 
taken up through a mechanism dependent of 
cytoskeletal reorganization and membrane 
remodelling with the morphological hallmarks 
of phagocytosis. Importantly, the properties of 
these aggregates not only determined the 
mechanism of internalization but also the 
involvement of the proteostatic machinery (the 
assembly of interconnected networks that 
control the biogenesis, folding, trafficking and 
degradation of proteins) in the process: while 
the internalization of small acidic aggregates is 
HSF1 independent, the uptake of larger basic 
aggregates was HSF1 dependent requiring 
Hsp70. Our results show that the biophysical 
properties of aggregates determine both their 
mechanism of internalisation and proteostatic 
response. It remains to be seen whether these 
differences in cellular response contribute to 
the particular role of specific aggregated 
proteins in disease. 
Recently it has been demonstrated that 
several disease-associated aggregates, including 
human (1–3) and yeast prions (4), Aβ (5), Tau (6), 
α-Synuclein (7), SOD1 (8) and PolyQ (9) can 
cross cellular membranes and spread aggregation 
from cell to cell (10). This has led to the notion 
that all these proteins potentially possess a certain 
degree of prionoid behaviour (8, 11, 12). Despite 
these reports the mechanism by which this process 
takes place remains obscure as the transmission of 
a protein or aggregate from the cytosol of one cell 
to the cytosol of a neighbouring cell requires the 
crossing of both cellular membranes. The 
existence of cell membrane translocation 
mechanisms has been proposed for some 
amyloids, such as nanotubules for prions (3) or 
membrane diffusion by an unknown mechanism 
for Aβ40 (13, 14) and α-Synuclein (15), although 
it is widely accepted nowadays that aggregate 
transmission can also occur through a combination 
of exocytosis, endocytosis and endosomal escape 
(16). 
In accordance with this hypothesis, several 
mechanisms of endocytosis and exocytosis have 
been postulated for the most common amyloids. 
Exocytosis by conventional exosomes, as the 
result of the fusion of multivesicular bodies with 
the plasma membrane, has been reported for 
monomeric Aβ (17), α-Synuclein (18–20), PrpSc 
(2, 21), and Tau (22) in neuroblastoma cell lines. 
Other unconventional exocytosis mechanisms 
have been described for PrP (23) and α-Synuclein 
(19). Endocytosis of monomeric Aβ (13, 14, 24–
26) and α-Synuclein (15, 27–29) and endocytosis 
of the fibrillar and oligomeric states of some 
amyloids have also been reported. For instance, 
fibrilar Aβ can be cleared from the medium by 
microglia and astroglia (30–32) while oligomeric 
Aβ can be taken up by neuroblastoma SH-SY5Y 
cells (33). The internalization of PrpSc aggregates 
has been reported in murine and human 
neuroblastoma cell lines and mouse fibroblasts, 
whereby heparan sulphates and lipid rafts turned 
out to be involved (1, 34–37). SOD1 aggregates 
are internalized by macropinocytosis by N2a cells, 
a neuroblastoma cell line (8), while Tau 
aggregates were taken up by HEK-293 cells and 
neuroblastoma cell lines (6, 38, 39). Currently it is 
not known whether different amyloids share 
common pathways of internalization. Besides, 
different pathways of internalization have been 
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described for the monomeric and fibrillar forms of 
α-Synuclein (15) and Aβ (13, 32), demonstrating 
that the aggregation status could also determine 
different routes of internalization. Finally, 
interaction of the native protein with natural 
partners could also determine specific handling by 
a specific subset of cells, as occurs during the 
intracellular production of Aβ (40, 41). 
Here our aim is to investigate whether the 
biophysical properties of an aggregating 
polypeptide sequence affects the way in which it is 
recognized and processed by the cell. As several 
competing uptake mechanisms have been 
previously described our objective here was 
therefore to design synthetic aggregating peptides 
with a strong bias towards a particular mode of 
uptake, which would illustrate how biophysical 
properties affect uptake and would allow to 
investigate pathway-specific cellular responses to 
aggregates. It is accepted that a size threshold 
determines the choice of the endocytic pathway 
that will be used for the uptake of different 
extracellular bodies. While particles below 0.5 µm 
in diameter could be internalized through clathrin, 
caveolin or general pinocytosis, particles of a 
bigger diameter will require the activation of a 
macropinocytic or phagocytic process (42). To this 
purpose, we have compared the internalization of 
two synthetic peptides with different aggregation 
propensities resulting in aggregate particles of 
different sizes. We found that aggregates of both 
peptides are efficiently internalized by non-
specialist cells in culture. Further aggregate size 
not only determine the mechanism of uptake but 
also modulate the involvement of the proteostasis 
machinery in the process. While large aggregates 
with a diameter bigger than 0.5 µm diameter were 
taken up by phagocytosis in a Heat Shock Factor 1 
(HSF1) dependent manner, smaller aggregates 
were internalized through fluid phase endocytosis 
in an HSF1 independent manner.  
Our work demonstrates that aggregate uptake 
is an inherent activity of mammalian cells. It also 
shows that biophysical parameters that affect the 
aggregation propensity and particle size determine 
the mode of uptake as well as the proteostatic 
response to aggregates: whereas larger aggregates 
are detected by the proteostatic machinery and 
actively internalized, smaller aggregates remain 
largely undetected and enter the cell in an 
unspecific manner.  
EXPERIMENTAL PROCEDURES 
Peptides and Reagents. Peptides PepL (sequence: 
RPILTIITLE RGSRRPILTI ITLE, Tango score: 
1273.17), PepS (sequence: DMISYAGMDP 
PDMISYAGMD, Tango score: 10.44), Inf12 
(sequence: RLIQLIVSRP PRLIQLIVSR, Tango 
score: 532.08) and Inf36 (sequence: 
RGVSILNLRP PRGVSILNLR, Tango score: 
29.36) were custom synthesized by JPT at a purity 
>95% as determined by HPLC. Lyophilised 
peptide powder was resuspended in DMSO to 2 
mM concentration. This DMSO stock solution was 
diluted to working solutions in PBS or cell culture 
medium ranging from 2 to 20 µM as indicated in 
each experiment. DLS analysis was performed in a 
DynaPro Plate Reader II (Wyatt Technology) 
equipped with a 830 nm wavelength laser and 
Dynamics software (Wyatt Technology) was used 
to analyse the data. The antibody against the 
extracellular region of membrane Hsp70, 
cmHSP70.1, was a kind donation of Prof. Dr. 
Gabriele Multhoff. The inhibitors dynasore 
hydrate, EIPA (5-(N-Ethyl-N-
isopropyl)amiloride), cytochalasin D, MβCD 
(Methyl-β-cyclodextrin), mevinolin, rapamycin 
and chlorpromazine hydrochloride were purchased 
from Sigma-Aldrich, KRIBB11 was obtained from 
Merck Chemicals, VER155008 from Tocris 
Bioscience and geldanamycin from Invivogen. 
Dextran 10000 MW conjugated to Texas Red was 
purchased from Life Technologies. Purified Hsp70 
was obtained from ENZO life sciences. Before cell 
culture incubations, storage solution was 
substituted by PBS in a Zeba Spin Desalting 
Column 7K (Thermo Scientific). 
Cell culture, transfections and peptide 
incubations. HEK-293 cell line was cultured in 
DMEM supplemented with 10% (v/v) FCS 
(Gibco), penicillin (100 U/ml) and streptomycin 
(100 U/ml). Proliferating cell cultures were 
maintained in a 5% CO2 humidified incubator at 
37°C. Transfections were performed with 
FuGENE HD (Promega) according to the 
manufacturer recommendations. Cellular 
expression of RFP fusions of proteins Rab5, Rab7 
and Lamp1 was achieved by the use of baculovirus 
based BacMam 2.0 probes (Life Technologies). 
GFP-LC3 expression was performed by 
transduction of cells with Lentibrite Lentiviral 
Biosensor following the manufacturer 
recommendations (Merck Milipore). For peptide 
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treatments of culture cells, 2 mM peptide stock 
solutions in DMSO were diluted to a 20 µM 
concentration in serum-free DMEM-F12 medium 
(Gibco) to allow the formation of aggregates 
before addition to the cells. Cells in culture were 
always at 90% confluency when peptide was 
added to the medium. For 20 µM incubations, 
cells were incubated for 1 hour in the peptide 
solution and then washed and incubated for 
different periods of time in complete cell culture 
medium. For 5 µM and 2 µM incubations, 20 µM 
peptide solutions were added to the cell culture 
medium as 4x or 10x concentrates respectively 
and no further wash steps were performed unless 
otherwise indicated. 
Immunofluorescence staining, in vivo 
confocal and time lapse confocal. Cell imaging 
was performed in vivo unless otherwise indicated 
using an inverted microscope (Nikon Eclipse 
TE2000-S) equipped with a Confocal Microscopy 
Imaging System (Nikon Eclipse C1). For time 
lapse experiments, a Nikon A1R Eclipse Ti was 
used. cmHsp70.1 staining was performed in vivo 
as follows: after overnight incubation in complete 
cell culture medium containing 5 µM peptide or 
10 µM geldanamycin, cells were first blocked in a 
solution of 20% goat serum and 0.2% tween-20 in 
PBS for 10 min and incubated right after for 1h in 
1:100 or 1:1000 antibody dilutions in PBS. Cells 
were then washed in PBS three times before being 
fixed in 4% paraformaldehyde in PBS. After 
fixation, cells were washed 3 times in PBS and 
mounted in ProLong Gold Antifade Reagent with 
DAPI (Life Technologies). High content analysis 
was performed in vivo in an IN Cell Analyzer 
2000 (GE Healthcare). The software IN Cell 
Developer was used for the quantification of the 
different structures. Internalised aggregates were 
differentiated from extracellular membrane-
attached aggregates by means of their higher 
fluorescence intensity. Small peripheral 
endolysosomes were distinguished by their smaller 
size. 
Transmission Electron Microscopy. For 
peptide aggregate solution analysis: 20 µM 
peptide suspensions in PBS were adhered onto 
carbon-coated copper grids and stained in a 
solution of 2% Uranyl acetate for 5 min. After 5 
rounds of washing in ultrapure water, grids were 
analysed in a JEM-1400 transmission electron 
microscope. Cell samples were grown on Aclar 
and incubated with peptide as described above. At 
given time points they were fixed overnight at 4˚C 
in 0.1 M sodium-cacodylate buffer containing 
2.5% glutaraldehyde. After washing, they were 
fixed additionally for 2 hours at 4˚C in 1% 
osmium tetroxide, rinsed with distilled water and 
dehydrated through a graded ethanol series. 
During the dehydration steps they were stained in 
3% uranyl acetate/70% ethanol for 30 min at 4˚C. 
After the last step in 100% ethanol, samples were 
washed in Propylene Oxide and embedded in 
Epoxy resin (Epoxy-Embedding Kit, Fluke 
Analytical). After polymerization, 50 nm slices 
were obtained and transferred to carbon-coated 
copper grids. Grids were subsequently post-stained 
for 10 min in 3% uranyl acetate/water and for 5 
min in a lead citrate solution (Reynolds’ 
formulation). After extensive washes in water, 
grids were air-dried and analysed in a JEM-1400 
transmission electron microscope. 
Microarrays. Cells were incubated with the 
different peptides as indicated above. After 24 
hours of incubation, total RNAs were extracted 
using RNeasy Mini Kit (QIAgen). RNA 
concentration and purity were determined 
spectrophotometrically using the Nanodrop 2000 
(Thermo Scientific) and RNA integrity was 
assessed using a Bioanalyser 2100 (Agilent, Santa 
Clara, CA, USA). Per sample, an amount of 100 
ng of total RNA spiked with bacterial RNA 
transcript positive controls (Affymetrix) was 
amplified and labelled using the GeneChip 3' IVT 
express kit (Affymetrix). All steps were carried 
out according to the manufacturer’s protocol 
(Affymetrix). A mixture of purified and 
fragmented biotinylated RNA and hybridisation 
controls (Affymetrix) was hybridised on 
Affymetrix GeneChip® PrimeView™ Human 
Gene Expression Arrays followed by staining and 
washing in a GeneChip® fluidics station 
450  (Affymetrix) according to the manufacturer’s 
procedures. To assess the raw probe signal 
intensities, chips were scanned using a 
GeneChip® scanner 3000 (Affymetrix). Raw data 
were processed all together with the RMA 
algorithm (43) and subsequently subjected to a 
two-factor ANOVA (analysis of variance). 
RESULTS 
Synthetic aggregation prone peptides with 
low and high aggregation propensities form 
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aggregate pools of largely non-overlapping size 
distributions in vitro. Most aggregating peptides 
and proteins form aggregates ranging from soluble 
oligomers to large insoluble inclusions. Moreover 
the size distribution of these aggregates evolves 
over time, which makes it difficult to isolate 
aggregates of a specific size-range in solution. In 
order to partially circumvent this difficulty, we 
used TANGO (44), an algorithm to predict protein 
aggregation, to select two peptide sequences with 
either low or high aggregation propensities with 
the aim of generating two aggregate populations 
with non-overlapping (or minimally overlapping) 
size-distributions over sufficient time to study the 
cellular internalization of these peptides.  
A peptide with low aggregation propensity 
and negative charge, referred to as PepS (for 
small, amino acid sequence 
DMISYAGMDPPDMISYAGMD, Tango score: 
10,44, pI=3.3) (Table 1), was derived from the 
vascular-endothelial growth factor receptor 2 
(VEGFR2) protein sequence. When put in solution 
in PBS at a concentration of 20 µM, amorphous 
aggregates of different sizes were observed by 
electron and confocal microscopy (Fig. 1A). 
Although particles above 1µm were occasionally 
observed, confocal images and DLS indicated that 
most of the peptide molecules were in a 
monomeric or oligomeric status (0.5 nm diameter) 
or in aggregates with a size distribution around 
100 nm (Fig.1B). A prolonged incubation for over 
a month at 37˚C with shaking at 1000 rpm did not 
increase the maximum size of the aggregates, 
although the amount of low molecular weight 
aggregates decreased in favour of the formation of 
aggregates of an approximate diameter of 500 nm 
(data not shown). 
The sequence of the highly aggregating 
positively charged peptide, referred to as PepL (for 
large, amino acid sequence 
RPILTIITLERGSRRPILTIITLE, Tango score: 
1280, pI=11.5) (Table 1), consists of a tandem 
repeat of an aggregation-prone sequence of the 
p53 DNA binding domain (45). Analysis by 
electron and confocal microscopy of a 20 µM 
solution of this peptide in PBS showed, as for 
PepS, a heterogeneous population of amorphous 
aggregates of different sizes but, contrary to PepS, 
confocal analysis of PepL solutions showed an 
enrichement in aggregates that typically exceeded 
1 µm diameter (Fig. 1A) although a population of 
aggregates of smaller size was also present (Fig. 
1A). DLS analysis confirmed that this solutions 
are mainly composed of aggregates well over 1 
µm in diameter (Fig. 1B). 
We therefore managed to select two 
aggregating peptide sequences displaying very 
different charge and size-distributions. 
Importantly, although the size distributions of 
PepS and PepL evolved over time, they remain 
distinct with PepS peptides never exceeding a 
maximum size of 500 nm while PepL immediately 
formed aggregates larger than 1 µm. 
PepL aggregates are fragmented on the cell 
surface prior to internalisation. PepL was added 
to the culture medium of HEK-293 cells at a 
concentration of 20 µM. After 1 hour incubation, 
association of the aggregates to the cell membrane 
could be detected after a medium change to wash 
away unbound aggregates (Fig. 2A). Time-lapse 
microscopy revealed that this association was not 
just deposition of the aggregates on the cell 
membrane, but rather a dynamic interaction 
between peptide aggregates and the cell 
membrane. Two main processes were observed in 
this interaction. On the one hand, the biggest 
aggregate particles were fragmented to smaller 
particles (Fig. 2A, upper panels, arrows, Video 1). 
On the other hand, aggregates were able to move 
along cells and even migrate from them to 
neighbouring cells (Fig. 2A, upper panels, arrows). 
In some cases, aggregates contacting the periphery 
of a cell moved towards perinuclear regions of it 
where they were engulfed (Fig. 2A, lower panels, 
arrowhead, Video 2). Confocal analysis in living 
cells confirmed that aggregate internalization was  
associated with fragmentation of large aggregates 
into smaller aggregates, rather than disaggregation 
into monomeric/single peptides. To visualize this 
we first prepared two separate solutions of 
aggregates, each labelled with a different 
fluorophore (Dylight#488 and Dylight#550) and 
subsequently mixed these together immediately 
before adding them to the cells. Upon mixing, both 
aggregates further matured into heterogeneous 
aggregates containing both labels (Fig. 2B, 1h). 
Rather than forming vesicles containing these 
heterogeneous aggregates, the internalized 
aggregates were generally labelled with only one 
of the fluorophores. Thus upon contact with the 
cell membrane aggregates are broken down to 
smaller units corresponding to premixing 
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aggregate nuclei rather than being disaggregated 
(Fig. 2B, 8h). 
PepL is internalized by phagocytic processes. 
The irregular morphology of the vesicles formed 
after internalization of the aggregates suggests 
phagocytic internalization. Following the process 
by TEM further corroborated this idea, showing 
contacts between aggregates and membrane, 
protrusions reaching over the surface of the 
aggregates and final engulfment (Fig. 2B, left 
panels). To corroborate this, a set of inhibitors of 
different endocytic pathways was used to better 
define the pathway implicated in aggregate 
internalization. To this end, high content analysis 
was performed, quantifying an average of 2000 
cells per sample for the presence and number of 
endocytic particles, which were discerned 
depending on their different size and fluorescence 
intensity (see Experimental Procedures). In our 
assay conditions, only a percentage of cells 
ranging from 10 to 40% takes up an average of 
one aggregate per cell. So the percentage of cells 
containing one aggregate in the population, rather 
than the number of aggregates internalized per 
cell, was used as measure of peptide uptake. This 
percentage was reduced by inhibitors like 
dynasore (inhibitor of dynamin-driven 
endocytosis), cytochalasin D (inhibitor of actin 
cytoskeleton reorganization), EIPA (inhibitor of 
the Na+/H+ pump) and acute treatment of the cells 
with MβCD (Methyl-β-CycloDextrin, a membrane 
cholesterol depletor) followed by chronic 
inhibition of cholesterol synthesis with mevanolin 
(Fig. 2C). All this inhibitors, although not specific 
for phagocytosis, have been previously described 
as phagocytosis inhibitors (46–49). On the other 
hand, uptake of the aggregates was not inhibited 
by a clathrin mediated endocytosis inhibitor such 
as chlorpromazine (Fig. 2C). Taking together the 
morphological and pharmacological data, the 
internalization of large aggregates formed by PepL 
is most likely due to phagocytic uptake.  
PepL disaggregation in endosomes is 
associated with endosomal swelling. Once 
internalized, the particles formed vesicles of 
irregular size with increased fluorescence levels 
(Fig. 2B, 8h). As the internalization progressed the 
endosomal vesicles expanded and increased their 
fluorescence intensity, probably due to 
fluorophore dequenching. Both facts suggest that 
peptide disaggregation into soluble monomeric or 
oligomeric peptides occurs in this vesicles (Fig. 2, 
24 h). The resulting enlarged endosomes are non-
homogenous. Their fluorescence intensity depicts 
an aggregated part of irregular shape at one pole 
surrounded by a rounded envelope of soluble 
material (Fig. 2B, 24h). TEM analysis confirms 
this arrangement as the micrographs clearly show 
aggregated material at one pole of the vesicle 
surrounded by smaller soluble peptide particles, 
which is again indicative of disaggregation activity 
(Fig. 2, 24h). Interestingly, these enlarged 
endosomal vesicles were particularly sensitive to 
photodisruption, as illumination with the confocal 
laser made the vesicles burst in a typically two-
phases event. In a first movement, illumination 
resulted in membrane contraction probably due to 
photo-oxidative membrane damage (Fig. 3A, 
panels 1-3, Video 3). This was then followed by 
vesicle dilatation until a final burst liberated its 
contents into the cytosol (Fig. 3A, panels 4-6, 
Video 3). These enlarged endosomal vesicles 
could also be observed by bright field microscopy 
with non-labelled peptide, excluding that vesicle 
swelling is a fluorophore-associated artefact (Fig. 
3B, panel 1, arrows). The structure remained 
morphologically identical after formaldehyde 
fixation when observed by bright field microscopy 
(Fig. 3B, panel 2, arrows). However after chemical 
fixation and permeabilization with detergents only 
the aggregated part of the enlarged endosomal 
vesicles remained, seeming like cytoplasmic 
inclusions of irregular shape by fluorescent 
microscopy (Fig. 3B, panel 3). Only under 
conditions of high background autofluorescence, 
e.g. when using glutaraldehyde fixation, the 
structure of the enlarged vesicle was fully 
depicted, as the empty vesicular part appeared 
black in contrast to the surrounding fixed cellular 
cytoplasmic content (Fig. 3B, panel 4, arrows). 
PepL aggregates are trafficked into the 
endolysosomal pathway. To characterize the 
vesicular trafficking of the aggregates, HEK-293 
cells were transfected with expression vectors of 
several fluorescently labelled endocytosis markers 
before being exposed to the aggregates. We 
observed that ruffled vesicles and enlarged 
endosomal vesicles were positive for Rab7 
staining and weakly positive for Rab5 staining 
(Fig. 4A, left panels), indicating that these 
compartments acquire late endosome properties 
rather quickly. Both ruffled and enlarged vesicles 
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also stained for the lysosomal marker Lamp1, 
indicating that fusion with lysosomes or late 
endosomes already took place (Fig. 4A, left 
bottom panels). After 8 hours of incubation, 
relatively small peripheral rounded vesicles 
containing the peptide were detected in the cells. 
These vesicles did not co-localize with the marker 
Rab5, but they did with markers Rab7 and Lamp1 
(Fig. 4A, right panels). Because the culture 
medium was refreshed after the first hour of 
incubation, these vesicles are more likely due to 
the distribution of material contained in ruffled 
and enlarged vesicles into peripheral 
endolysosomes, rather than to fluid phase 
endocytosis of soluble peptide still present in the 
extracellular solution. 
Despite Rab5 being just weakly visible in the 
membranes of the vesicles, its function is 
necessary for the progression of the peptides 
through the endosomal compartment. In fact, the 
expression of a constitutively active mutant of this 
protein (Rab5Q79L) prevented the distribution of the 
peptide to the peripheral endolysosomes (Fig. 4B). 
PepS is trafficked to the endolysosomal 
pathway by fluid phase endocytosis. The pathway 
of internalization of peptide PepS was different 
from that of PepL from both a morphological and 
a functional perspective. First, contrary to PepL, 
confocal imaging did not detect any association of 
PepS with the cell membrane (Fig. 5A). Further, 
the uptake of PepS was similar in time and 
morphology to the internalization of a fluid phase 
marker (TexasRed-Dextran10) suggesting a 
mechanism of fluid phase endocytosis (Fig. 5A). 
Thus, the internalization of this peptide takes place 
through the formation of vesicles of a diameter 
ranging from 0.5 µm to 1 µm that increase 
progressively in fluorescence intensity over time, 
indicating peptide accumulation (Fig. 5A). The 
effect of specific endocytic inhibitors was also in 
agreement with fluid phase endocytosis as only 
partial inhibition of this process could be achieved. 
Through high content microscopy analysis, this 
decrease in the uptake can be quantified as a 
reduction of the number of detectable intracellular 
vesicles. Dynasore is the inhibitor with the biggest 
impact, reducing the intracellular number of 
vesicles to 50% in treated cells (Fig. 5B). The 
macropinocytosis inhibitor EIPA has a marginal 
impact on the number of vesicles detected 
indicating that most of the peptide is internalized 
through other pathways. Inhibition of the 
cytoskeleton dynamics by cytochalasin D showed 
a decrease in the number of vesicles of about 25% 
(Fig. 5B). This could be due to a decrease in the 
phagocytosis or macropinocytosis of the particles 
of bigger size present in the solution. Finally, 
chlorpromazine showed an increase in peptide 
uptake both in number and size of the vesicles 
(Fig. 5B), which suggests a compensation effect 
on endocytic uptake through clathrin independent 
endocytosis, such as pinocytosis and 
macropinocytosis. Overall, the partial and 
compensatory effects caused by the inhibitors 
indicate that the peptide was internalized as bulk 
in the fluid phase during constitutive endocytosis 
and not as a result of specific membrane 
recognition, signalling and uptake.  
The use of the endocytosis markers described 
earlier showed that vesicles that accumulate 
peptide were positive for Rab7 and Lamp1 (Fig. 
5C). Rab5 positive vesicles were spotted as well, 
more abundantly at short incubation times (Fig. 
5C). Overexpression of the constitutively active 
mutant Rab5Q79L induced an arrest of the 
internalized PepS in early endosomes (Fig. 5C), as 
shown before for PepL. Together this indicates 
that both PepS and PepL trafficking converge 
towards endolysosomal pathways. 
PepL and PepS differ in several biophysical 
parameters, such as pI, hydrophobicity and 
aggregation propensity, which can modify their 
mechanism of interaction with membranes. It has 
been described that electrostatic interactions play 
an important role in protein-membrane 
interactions, and therefore the difference in net 
charge of the peptides could influence the 
difference in uptake mechanism. To rule out this 
possibility we studied the cellular uptake of 
another set of peptides that have the same charge 
and similar mean hydrophobicity but only differ in 
their aggregation propensity. These peptides, 
called Inf12 and Inf36, are derived from 
aggregating stretches found in the basic 
polymerases 1 and 2 (PB1 and PB2) of the 
Influenza A virus (Inf36 RGVSILNLRP 
PRGVSILNLR and Inf12 RLIQLIVSRP 
PRLIQLIVSR, respectively) (Table 1). Having 
very different tango scores (29 and 532, 
respectively) they form small aggregates (79% of 
particles in solution are about 200 nm) and larger 
aggregates (64% of aggregates around 10 µm) 
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respectively (Fig. 1). Corroborating our previous 
results, the highly aggregating peptide Inf12 was 
internalized through the formation of large 
cytosolic inclusions as observed for peptide PepL 
(Fig. 6, upper panels, arrows). On the other hand, 
Inf36, the least aggregating peptide, was taken up 
through a mechanism resembling fluid phase 
endocytosis (Fig. 6, lower panels), with gradual 
accumulation of peptide over time in relatively 
small intracellular compartments, as observed for 
PepS. Although this additional experiment does 
not resolve the particular biophysical factors 
determining aggregate uptake these results suggest 
that aggregate size plays an important modulating 
role on the mode of aggregate uptake by cells. 
PepL but not PepS internalisation requires 
Hsp70 and is HSF1 dependent. As phagocytosis is 
a specific and active process, our results suggested 
that extracellular aggregates were specifically 
recognized as cargo and internalized upon 
intracellular signalling. We therefore analysed the 
role of the protein quality control system (PQC) 
during aggregate internalisation. The PQC consists 
of chaperones, which assist protein folding and 
trafficking, and the degradation machinery, 
comprised mainly of the proteasome and 
autophagy systems working independently or in 
collaboration with ubiquitin-ligases (50–52). 
Besides, dedicated transcription factors promote 
the expression of the necessary PQC components 
upon proteotoxic stimuli. Among these 
transcription factors, the Heat Shock Factor 1 
(HSF1) has a prominent role (53). 
HEK-293 cells were treated before and during 
incubation in medium containing aggregating 
peptides with inhibitors of the chaperones Hsp70 
(VER155008) and Hsp90 (geldanamycin), a 
specific inhibitor of HSF1 (KRIBB11) and an 
autophagy stimulator (rapamycin). Treatment with 
VER155008 decreased the number of cells 
containing internalised PepL to 20% with respect 
to the untreated controls, indicating prominent role 
for Hsp70 in PepL aggregate uptake (Fig. 7A). 
Consistent with the above result, inhibition of 
HSF1 produced a similar inhibition pattern (Fig. 
7A), showing that the uptake of large extracellular 
aggregates requires a proteostatic response. 
Contrary to PepL, the uptake of PepS was not 
affected by VER155008 or KRIBB11 since the 
use of these inhibitors didn't decrease the amount 
of peptide being internalised by cells (Fig. 7A). 
This indicates that fluid phase endocytosis of 
small aggregates is unspecific and HSF1 
independent. As a control for the specificity of the 
Hsp70 inhibitors in aggregate uptake, 
phagocytosis of polystyrene beads of 3 µm of 
diameter was tested in the presence of the 
aforementioned inhibitors. Bead uptake was 
efficiently blocked by endocytosis inhibitors such 
as cytochalasin D but, on the contrary, none of the 
PQC inhibitors tested, including KRIBB11 and 
VER155008, had negative effects on bead 
internalisation (Fig. 7A), which argues for a 
specific role of Hsp70 in the uptake or endosomal 
trafficking of extracellular aggregates rather than a 
general role in phagocytosis or macropinocytosis 
of any type of particle.  
Geldanamycin treatment did not reduce the 
number of cells internalising PepL aggregates, nor 
the number of internalised aggregates per cell (not 
shown), although the number of peripheral 
endolysosomes per cell decreased (Fig. 7A). Since 
the number of cells with internalised aggregates is 
the same as in untreated cells, the reduction in the 
number of endolysosomes can only be explained 
by a role of Hsp90 in endosomal trafficking 
between early endosomes and lysosomes (54). 
Geldanamycin also affected the endosomal 
trafficking of PepS. In this case, we observed an 
increase in the average endosome size  associated 
with a 40% decrease in the number of peptide-
containing vesicles (Fig. 7A). 
Finally, autophagy has been implicated in the 
degradation of intracellular aggregates through 
chaperone mediated mechanisms (51). We 
examined the role of autophagy in the cellular 
trafficking of internalised aggregates using 
rapamycin. After incubation of cells with PepL, 
we did not observe any change in the uptake 
efficiency or the number or size of the intracellular 
compartments containing the peptides in 
rapamycin treated cells (Fig. 7A). To further study 
the role of autophagy, we assayed the 
internalisation of PepL in cells transduced with a 
GFP-LC3 expression vector that allows 
visualization of autophagosomes. The expression 
of this protein generated a cellular diffuse staining 
with the occasional presence of autophagosomes 
appearing as bright small vesicles (Fig. 7B, 
arrows). When cells expressing this GFP-LC3 
protein were incubated with peptide PepL, no 
increase in the number of autophagosomes nor 
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colocalization between LC3 and the vesicles 
containing the peptides was detected (Fig. 7B). 
We therefore concluded that a role of autophagy in 
the processing of extracellular aggregates is 
unlikely. 
Gene-expression analysis reveals a 
proteostatic response upon PepL uptake. The fact 
that KRIBB11 had an inhibitory effect on 
aggregate uptake suggests a proteostatic response 
of cells challenged by large aggregates. We 
analysed the cellular response to the presence of 
aggregates by mRNA microarray analysis at 
different time points of internalisation (8h and 24h 
after incubation). Changes in expression levels 
were evaluated using ANOVA with a significance 
threshold of p<0.01. Overall, PepL internalisation 
had a larger effect than PepS on the gene 
expression profile of HEK293 cells, both in terms 
of the number of affected genes (626 versus 377 
after 24h) as on the magnitude of the changes 
(maximum fold change of 2.4 versus 1.5). 
Interestingly, there is only little overlap in gene-
expression changes induced by PepS and PepL 
internalisation (4.5% after 8h, 4% after 24h). 
Looking at proteostatic changes in particular again 
confirmed a larger effect of PepL internalisation. 
Notably, we observed the upregulation of the 
Hsp70 family of chaperones and their co-
chaperones of the Hsp40 family upon PepL but not 
PepS incubation (Fig. 7C). In accordance with 
this, we also observed the upregulation of the 
chaperone Hsp110 (HSPH1), that has been 
recently described as part of the cytosolic 
machinery responsible for the disaggregation of 
peptide aggregates (55–57). The other two main 
elements of the disaggregating complex, Hsp40 
(DNAJA1) and Hsp70 (HSPA1A) were also 
upregulated in cells incubated with PepL (Fig. 
7C). Many of these chaperones have been 
described as targets of HSF1 (Fig. 7C, 
highlighted). Although biologically relevant given 
the effect of HSF1 inhibition on aggregate uptake, 
the fold changes we found in response to 
aggregate uptake were low in comparison to the 
changes previously reported after heat shock and 
HSF1 activation, suggesting PepL internalisation 
induces a more subtle and less acute proteostatic 
response than thermal stress (58, 59). 
Hsp70 inhibits PepL internalisation by 
blocking membrane interactions. To study the role 
of Hsp70 in aggregate uptake we first explored a 
possible extracellular activity of Hsp70. 
Preincubation of PepL with Hsp70 for 1h before 
adding it to the cells reduced the number of 
internalised aggregates to 20% after 24 hours of 
incubation (Fig. 8A). Importantly, the inhibitory 
effect could already be detected in the number of 
aggregates attached to the cell membranes within 
the first 2 hours of incubation (Fig. 8A, 2h). This 
decreased affinity for cell membranes is therefore 
the cause of the decreased internalisation. The 
subsequent trafficking of the aggregates after 
engulfment and their distribution to 
endolysosomes remained unaltered compared to 
control cells. This went along with a decreasing 
number of internalised aggregates after 48 h and 
an increasing number of endolysosomes as the 
result of aggregates being processed and targeted 
for lysosomal degradation (Fig. 8A). Importantly, 
the preincubation of PepL aggregates with Hsp70 
inhibited their attachment and internalisation more 
efficiently than the simultaneous addition of 
aggregates and Hsp70 (Fig. 8A). This indicates 
that Hsp70 can alter the affinity of aggregates for 
the cell membrane by binding to areas on the 
aggregate that are required for their recognition, 
rather than by affecting cellular endocytic activity 
through the modulation of cell signalling pathways 
or the modification of components of the cell 
membrane. This view is confirmed by the co-
immunoprecipitation of Hsp70 with pepL (Fig8E) 
Although we observed a strong blockage of 
aggregate uptake by inhibiting the ATPase activity 
of Hsp70 with VER155008 (Fig. 7A), aggregate 
attachment was not affected by treatment with this 
inhibitor, since it did not decrease the number of 
PepL aggregates attached to cell membranes as 
compared to the untreated controls after 2 hours of 
incubation (Fig. 8B, upper panel). This implies 
that Hsp70 must be implicated in another step of 
peptide internalisation, for which Hsp70 
chaperoning and ATPase activity are required. 
Blocking this step did not prevent the aggregates 
to attach to the membrane, since they remained 
associated and could be internalised upon removal 
of the inhibitor (Fig. 8B, upper panel, 24 and 48 
hour time point). Comparably, membranes 
depleted of cholesterol by MβCD treatment 
showed the same affinity for PepL as the untreated 
controls (Fig. 8B, lower panel, 2h). Following 
MβCD removal, the subsequent uptake of the 
aggregates that were already attached to the 
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membrane was prevented by the continuous 
inhibition of cholesterol synthesis by mevanolin 
for 24h (Fig. 8B, lower panel). Removal of this 
inhibitor allowed the cells to restart peptide uptake 
after 24 h so these cells presented a similar amount 
of internalised aggregates to that of untreated 
controls (Fig. 8B, lower panel, 48 hour time 
point). This implies that cholesterol enriched lipid 
membrane rafts are not required for aggregate 
association to the membrane, though they may be 
important in the intracellular signalling leading to 
their internalisation. 
To investigate why blocking PepL with 
soluble Hsp70 would impede recognition, we next 
tested whether membrane Hsp70 could be working 
as a receptor for the aggregates. We therefore 
blocked the extracellular exposed region of the 
membrane-inserted Hsp70 with a specific antibody 
(60). As shown in Figure 8C, a 1 hour 
preincubation of HEK-293 cells with this antibody 
did not prevent attachment, internalisation or 
processing of PepL aggregates in treated cells and 
resulted in a number of extracellular attached 
aggregates, internalised aggregates and 
endolysosomes comparable to the detected in 
untreated controls (Fig. 8C). In addition, we could 
not detect the presence of membrane Hsp70 in 
peptide-treated or control cells by confocal 
microscopy (Fig. 8D, right panels). By contrast, 
treatment of the cells with geldanamycin induced 
the translocation of Hsp70 to membrane patches 
resembling the previously described in the 
literature (61) (Fig. 8D, left panels). This result 
seems to rule out the possibility of direct 
interaction between Hsp70 and peptide aggregates 
on the cellular membrane. 
DISCUSSION 
We have described two pathways of entry of 
aggregating peptides in human cultured cells: fluid 
phase uptake of small aggregates and the 
internalisation of large aggregates by phagocytosis 
both of which are channelled into the 
endolysosomal system. Based on our experimental 
data, we propose that these two pathways occur by 
default in cells for the uptake of a given peptide in 
solution and are not mutually exclusive. Therefore 
a mixed solution containing both monomeric or 
oligomeric soluble peptide and large aggregates of 
several microns in diameter will be taken up by 
cells using both mechanisms. Importantly, the 
fluid phase uptake that we described is active for 
peptide whose sequences are not specifically 
attached to membranes. In cases where specific 
recognition of a peptide occurred, cells may use 
different endocytic mechanisms such as clathrin, 
caveolin or membrane translocation that would 
speed up their internalization with respect to this 
fluid phase uptake. Membrane association has 
been described previously in different models. For 
instance, charge dependent affinity for heparan 
sulfates is common in several cell penetrating 
peptides and amyloids (25, 34, 62). In the case of 
aggregating peptides, several amyloids have been 
proposed to be recognized by other membrane 
receptors, mostly of the TLR and scavenger 
families (26–31). Besides, it has been shown that 
amyloid conformation could determine membrane 
adhesion of small oligomers (63). Our results 
indicate that strongly aggregating peptides could 
reach a size that favours interaction with cell 
membranes regardless of their amyloid or 
amorphous organization, although the nature of 
this interaction remains to be investigated. 
The internalisation of soluble amyloidogenic 
species has been previously described in cell 
culture for α-synuclein (15, 28) and both in cell 
culture and in vivo for Aβ (14, 24) either by 
specific uptake through receptor mediated 
endocytosis or passive diffusion across the cell 
membrane. In the case of Aβ, the internalisation of 
soluble species has been demonstrated to promote 
maturation into larger aggregates due to the acidic 
pH and increased concentration generated in the 
lysosomes. It is difficult to infer whether in vivo 
intracellular accumulation could be achieved only 
by unspecific intake during constitutive 
endocytosis. However, lysosomal accumulation of 
Aβ relies on a very slow rate of endocytosis 
together with a slow degradation rate (24), which 
are characteristics common to the mechanism 
described here. It is therefore possible that 
unspecific fluid phase endocytosis could 
contribute to the internalisation of aggregates in 
vivo. 
Phagocytosis of extracellular aggregates by 
specialized cells is a documented feature of 
amyloid diseases. Microglia and astrocytes have 
been reported as fundamental in the clearance of 
Aβ plaques both in vivo and in cell culture (64, 
65). Despite professional phagocytes being 
responsible for this function in vivo, it must be 
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considered that most of the non-professional 
phagocytic cell lines are capable of phagocytosis. 
Therefore it cannot be excluded that, in 
circumstances of increasing amyloid deposition in 
the extracellular space, non-professional 
phagocytic cell lines also internalise aggregated 
material, in the same way they do here when 
aggregates are directly decanted on their 
membranes in cell culture. In this regard, it must 
be considered that HEK-293 cells in our 
experiments required a minimum of 8h to 
complete engulfment of the phagocytized particles 
while Aβ-activated microglia can internalise 
microspheres in just 30 minutes (66). This is 
probably a reflection of the lack or low abundance 
of specific receptors in the cell membrane 
responsible for the recognition of the aggregating 
species such as Toll-like, scavenger, complement 
and Fc receptors. 
PepL internalisation by phagocytosis is 
strongly decreased by chemical inhibition of 
Hsp70 function, which did not affect the 
internalisation of the smaller PepS aggregates by 
fluid phase internalisation. Moreover, exposure to 
the bigger basic PepL aggregates induced an 
upregulation of the Hsp70 expression level, while 
this remained unaffected in cells treated with the 
smaller acidic PepS aggregates. Both results argue 
in favour of a role for Hsp70 in the internalization 
of aggregates larger than 1 µm. Several possible 
functions of Hsp70 could explain these results. 
First, Hsp70 could be part of a chaperone-receptor 
complex on the cell membrane with adaptor roles 
between aggregate recognition and cell signalling. 
On the other hand, Hsp70 could be needed for its 
chaperoning action on components of the 
phagocytic machinery in an analogous way to its 
chaperone activity on clathrin (67). Finally, 
cytosolic Hsp70 could be regulating signal 
transduction pathways activated upon aggregate 
recognition. In any case, its function must be 
specific for aggregate recognition, since inhibition 
of Hsp70 activity did not alter the efficiency of the 
uptake of polystyrene beads. In this context, it 
must be as well considered that Hsp70 is part of 
the disaggregating complex formed together with 
Hsp40 and Hsp110 to promote disaggregation of 
intracellular aggregates. More importantly, the 
inhibition of Hsp70 activity with VER155008 
halts the function of the whole disaggregating 
complex, so a possible dependency of aggregate 
uptake on disaggregase activity cannot be ruled 
out (55). It is relevant to point out that the 
morphological changes in the vesicles containing 
internalised aggregates, which are mostly vesicle 
growth to accommodate soluble material, are 
consistent with an intravesicular disaggregase 
activity. Regardless of the mechanism Hsp70 is 
implicated in, exposure to a high concentration of 
extracellular aggregates might sequester Hsp70 
function, eliciting a compensatory chaperone 
response at the transcriptional level. This response 
is probably mediated by HSF1, since its specific 
chemical inhibition also partially inhibited 
aggregate uptake in our experiments.  
Finally, several lines of work have 
demonstrated an important neuroprotective role 
for extracellular Hsp70 and other chaperones such 
as clusterin against the toxicity of several 
amyloids (68–70). This protective action has been 
attributed to the refolding and aggregation-
inhibiting activity of the chaperone and to the 
activation of phagocytic cell types through 
membrane receptors to which Hsp70 binds directly 
(71, 72). In a complementary way, we have 
demonstrated here that extracellular Hsp70 can 
inhibit the interaction of peptide aggregates with 
cellular membranes without changing their 
aggregation status, which may have a large impact 
on the toxicity and extracellular clearance of 
aggregates from the intercellular space. In 
particular, as contact of extracellular Hsp70 with 
Toll-like receptors has been shown to activate 
phagocytosis by macrophages and microglia (71, 
72), the inhibition of membrane interactions of 
aggregates with non-specialist cells might be an 
added advantage.  
In conclusion, the results presented here show 
that cellular responses to extracellular aggregating 
peptides vary greatly depending on the biophysical 
properties of the aggregates including aggregation 
propensity and aggregate size and charge. While 
aggregates exceeding a diameter of a micron need 
specific membrane recognition and phagocytosis 
to enter the intracellular endosomal compartment 
of the cells, smaller aggregates are internalised 
unspecifically through fluid phase endocytosis. 
Importantly, large aggregates require aggregate-
specific Hsp70 chaperone activity to be 
internalised and trigger a chaperone response in 
the cells. Further studies will be necessary to 
evaluate the actual role of Hsp70 in aggregate 
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recognition and uptake, which could represent a 
link for the transmission of extracellular 
proteostatic stresses into intracellular heat shock 
responses. 
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FIGURE LEGENDS 
TABLE 1. Sequence, aggregation propensity and isoelectric point of the peptides used throughout 
this study. amino acids were coloured according to the properties of their side chains: blue, positively 
charge; red, negatively charged; green, aliphatic; grey, polar; purple, aromatic; orange, glycines; black, 
prolines. pI: isoelectric point. 
FIGURE 1. Size analysis of PepL and PepS. A. Microscopic observation of the peptide solutions. 
Left panels. Electron microscopy. 20 µM solutions in PBS of FITC-conjugated peptides were 
negatively stained with uranyl acetate for TEM analysis. Scale bar: 1 µm. Right panels. Confocal 
microscopy. Peptides conjugated to Dylight#488 were resuspended in PBS to 20 µM and observed at the 
confocal microscope. Scale bar: 10 µm. B. DLS analysis of the peptide solutions. Size distribution of 
the aggregates present in 20 µM solutions in PBS of FITC-conjugated peptides were obtained by 
differential light scattering. The distributions were obtained by adjustment to a cumulant fit of the 
autocorrelation curves of 50 measurements of 5 s per sample. d: diameter. 
FIGURE 2. Internalisation of PepL. A. Time lapse imaging of peptide aggregates in contact with 
cell membranes. HEK-293 cells were incubated in medium containing 20 µM PepL-Dylight#488 and 
observed in vivo at the confocal microscope. Peptide is shown in green over bright field images. Upper 
panels. Fragmentation of aggregate conglomerates and intercellular movement of aggregates. Lower 
panels. Aggregate movement from the periphery to perinuclear areas. A white dotted line was drawn 
around the nucleus for clarity. Scale bar: 10 µm. B. Internalisation of PepL aggregates by confocal 
microscopy and TEM. Left panels: HEK-293 cells were incubated in culture medium containing 20 µM 
PepL. At the indicated time points cells were fixed in glutaraldehyde and processed for TEM. Membrane 
interaction is shown in the upper panel (1 h), engulfment in the middle panel (8 h) and an “enlarged” 
vesicle is shown in the lower panel (24 h). Aggregated material is marked with an asterisk. Arrows 
indicate cellular protrusions. Nuclei are indicated with an “n”. Scale: 1 µm. Right panels. HEK-293 cells 
were exposed to conglomerates of aggregates formed by Dylight#488 (green) and Dylight#550 (red) 
conjugated PepL (see text for details) and observed by confocal microscopy. Nuclei were stained with 
Hoechst (cyan). Scale bar: 10 µm. C. Selective chemical inhibition of endocytic pathways. HEK-293 
cells were incubated in medium containing 5 µM PepL-Dylight#488 in the absence (mock) or presence of 
the indicated inhibitors at the following concentrations: 10 µM dynasore, 100 µM EIPA, 1 µM 
cytochalasin D, 10 mM MβCD followed by 10 µM mevinolin, 15 µM chlorpromazine. The number of 
cells containing internalised aggregates was quantified by high content analysis in vivo after 24h of 
incubation. The percentage of cells with aggregates with respect to the total was calculated for each 
condition and represented as the fold ratio with respect to untreated cells. Error bars represent the 
standard deviation of 3 independent experiments performed in duplicate. Statistical significance after 
ANOVA analysis with Tukey post-test indicated as follows: (●) α ≤ 0.05; (*) α ≤ 0.01; (**) α ≤ 0.001, 
(***) α = 0. 
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FIGURE 3. Morphological analysis of enlarged vesicles. A. Photodisruption. A. A HEK-293 bearing 
an enlarged vesicle containing a PepL aggregate was illuminated constantly with the confocal laser 
(Argon 488 nm) for 15 min. Morphological changes in the vesicle were followed by time lapse confocal 
microscopy. 1) 30 seconds. 2) 3 min 3) 9 min 4) 13 min 5) 14 min. 6) 15 min. B. Fixation artefacts. 
HEK-293 cells were incubated for 24 h with PepL-Dylight#488 aggregates and imaged by: bright field 
microscopy in vivo (1),bright field after fixation in 4% formaldehyde for 20 min (2) and confocal 
microscopy after fixation in 4% formaldehyde (3) or 2.5% glutaraldehyde(4) followed by 
permeabilization in 0.1% Triton X-100. Green: PepL, Red: autofluorescence. Enlarged vesicles are 
indicated by arrows. Scale bar: 10 µm. 
FIGURE 4. Endocytic pathways of peptide PepL internalisation. A. Endocytic markers. HEK-293 
cells expressing the RFP-fusion proteins (red) indicated were incubated in medium containing 20 µM 
PepL-Dylight#488 (green). The internalisation process was followed by life confocal imaging at the 
indicated time points. B. Early endosome function inhibition. Cells expressing the constitutively active 
mutant Rab5Q79L were incubated in culture medium containing 20 µM PepL-Dylight#488 and imaged as 
in A. Scale bar for A. and B.: 10 µm.  
FIGURE 5. Endocytic pathways of peptide PepS internalisation. A. Dextran10 co-incubation. HEK-
cells were incubated in medium containing 20 µM Dextran10-TexasRed (red) in the presence or absence 
of 20 µM PepS-Dylight#488 (green). The internalisation process was followed by life confocal imaging at 
the indicated time points. Medium was removed just before imaging at each time point to remove 
background fluorescence. Scale bar: 20 µm. B. Selective chemical inhibition of endocytic pathways. 
HEK-293 cells were incubated in medium containing 5 µM PepS-Dylight#488 in the absence (mock) or 
presence of the indicated inhibitors at the concentrations indicated in Fig. 2C. The number of fluorescent 
vesicles per cell after 24h of incubation was quantified by high content analysis in vivo and represented as 
the fold ratio with respect to untreated cells. Error bars represent the standard deviation of 3 independent 
experiments performed in duplicate. Statistical significance indicated as in Fig. 2C: (●) α ≤ 0.05; (*) α ≤ 
0.01; (**) α ≤ 0.001, (***) α = 0. C. Endocytic markers. Cells expressing the indicated RFP-fusion 
proteins (red) were incubated in medium containing 20 µM PepS-Dylight#488 and imaged at the 
indicated time points by in vivo confocal microscopy. Scale bar: 20 µm. 
FIGURE 6. Internalization of peptides Inf12 and Inf36. HEK-293 cells were incubated in medium 
containing 5 µM concentrations of peptides Inf12-Dylight#488 or Inf36-Dylight#488. The internalization 
was followed by in vivo confocal microscopy. Images were taken at the indicated time points. Arrows: 
intracellular inclusions. Scale bar: 10 µm 
FIGURE 7. Role of the protein quality control system in the internalisation of aggregating peptides. 
A. Selective chemical inhibition of various agents of the protein quality control system. HEK-293 
cells were incubated in medium containing 5 µM concentrations of peptides PepL-Dylight#488 or PepS-
Dylight#488 or in a 1% suspension of polystyrene microspheres (3 µm diameter Fluoresbrite 
Microparticles -Polysciences, Inc-) in the absence (mock) or presence of the following inhibitors: 10 µM 
KRIBB11, 40 µM VER155008, 10 µM geldanamycin, 100 nM rapamycin and 1 µM cytochalasin D. 
Different quantifications of size and number of the different vesicle types and beads were performed by 
high content analysis in vivo after 24h of incubation. Error bars represent the standard deviation of 3 
independent experiments performed in duplicate. Statistical significance indicated as for Fig. 2C: (●) α ≤ 
0.05; (*) α ≤ 0.01; (**) α ≤ 0.001, (***) α = 0. B. LC3 localization. HEK-293 cells expressing a 
fluorescent fusion protein GFP-LC3 (green) were incubated in medium containing 5 µM PepL-
Dylight#550 (red) and analysed by in vivo confocal microscopy. Images were captured after an overnight 
incubation. C. Expression levels of several representative members of the quality control system 
after incubation with aggregating peptides. HEK-293 cells were incubated for 24h in medium 
containing 5 µM PepL or PepS. Cells were then lysed and total mRNAs were extracted, purified and 
hybridized in an expression profile microarray (Affymetrix Human PrimeView). Green bars indicate 
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upregulated genes and red bars downregulated genes for each of the peptides. Expression levels are the 
average of three independent experimental replicates and are represented as the fold change with respect 
to untreated controls. 
FIGURE 8. Role of Hsp70 in the internalisation of PepL aggregates. A. Extracellular addition of 
Hsp70 protein. A mixed solution of 6 µM PepL and  1.2 µM Hsp70 in PBS was incubated at 37°C for 1h 
and then added to the culture medium of HEK-293 cells at a 90% confluency to a final concentration of 2 
µM PepL and 400 nM Hsp70 (green bars, “preincubation”). Alternatively, a PepL/Hsp70 solution at the 
same concentration was added to cells without any previous incubation (red bars, “simultaneous 
addition”). As a negative control, a solution containing only 6 µM PepL was added to the cell culture 
medium (blue bars, “mock”). To measure the amount of peptide attached to the cell membranes, the 
solution containing the peptide was removed after 1h incubation and cells were washed twice with 
complete medium. The number of aggregates remained attached to cell membranes was then quantified 
by high content analysis (time point “2h”). 24 and 48 hours after peptide addition, the number of 
internalised aggregates (upper panel) and endolysosomes (lower panel) was also quantified by high 
content analysis. A dotted vertical grey line separates the time points where extracellular aggregates were 
quantified from time points showing intracellular aggregates. B. Effect of Hsp70 inhibition and 
cholesterol depletion on aggregate membrane attachment. HEK-293 cells were incubated in medium 
containing 5 µM PepL-Dylight#488 in the absence (mock) or presence of the indicated inhibitors. Upper 
panel: after a 1 hour incubation in the absence or presence of 40 µM VER155008, medium was removed 
and cells were washed twice in complete cell culture medium and incubated without inhibitor for the 
indicated time periods. Lower Panel: after a 1h incubation in 10 mM MβCD cells were washed twice in 
complete medium and incubated in medium containing 10 µM mevinolin (“MβCD/Mevinolin”) or in the 
absence of inhibitors (“Mock” and “MβCD”). After additional 24 hours, mevinolin was removed by two 
medium washes and cells were incubated for 24h more (48h time point). The number of attached 
extracellular and internalised aggregates was quantified as indicated in section A. C. Hsp70 blocking 
antibodies. cmHsp70.1 antibody was diluted in the culture medium of HEK-293 cells to the indicated 
concentrations and incubated for 1 hour. A solution of PepL was then added to the culture medium to a 
final concentration of 5 µM.  After a 1 hour incubation, medium was removed and cells were washed 
twice and incubated in complete cell culture medium for the indicated time points. The number of 
attached extracellular and internalised aggregates was quantified as indicated in section A. D. Membrane 
Hsp70 staining. HEK-293 cells were either treated with 10 µM geldanamycin or 5 µM peptide PepL-
Dylight#550 (red) or left untreated. After an overnight incubation cells were stained for 
immunofluorescence with antibody cmHsp70.1-Cy2 (green) and fixed. In samples incubated with 
aggregates, peptide autofluorescence is responsible for the green signal observed in both antibody-treated 
and untreated cells samples. Scale bar: 20 µm. 
  






Peptide Sequence Tango score pI 
PepL RPILTIITLERGSRRPILTIITLE 1273.17 11.52 
PepS DMISYAGMDPPDMISYAGMD 10.44 3.32 
Inf12 RLIQLIVSRPPRLIQLIVSR 532.08 12.48 
Inf36 RGVSILNLRPPRGVSILNLR 29.36 12.48 








